ONT-093
Based on 1 Customer Validation
ONT-093 (OC 144-093) is a potent and orally active inhibitor of P-glycoprotein pump. ONT-093 inhibits P-gp-mediated ATPase activity with an IC50 of 0.16 μM. ONT-093 can inhibit drug efflux and increase bioavailability. ONT-093 reverses cancer cells multidrug resistance to chemotherapeutic drugs. ONT-093 can be used for the researches of cancer and infection, such as colon cancer and malarial .
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 98.79%
- CAS 番号: 216227-54-2
- 分子式: C32H38N4O
- 分子量:494.67
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
生物活性
製品説明
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CCRF-CEM | ED50 |
0.05 μM
Compound: 22
|
Modulation of Pgp (P-glycoprotein) mediated multidrug resistance in CEM / VLB 1000 cell line
Modulation of Pgp (P-glycoprotein) mediated multidrug resistance in CEM / VLB 1000 cell line
|
[PMID: 11128633] |
体外実験
ONT-093 reverses multidrug resistance (MDR) to Doxorubicin (HY-15142A), Paclitaxel (HY-B0015), and Vinblastine in lymphoma, breast, ovarian, uterine, and colorectal carcinoma cell lines expressing P-glycoprotein with an average EC50 of 0.032 μM[1].
ONT-093 shows no cytotoxic against 15 normal, nontransformed, or tumor cell lines, with an average cytostatic IC50 of >60 μM[1].
ONT-093 (10 μM) reverses the diminished Halofantrine (HY-A0148) accumulation by pfmdr1Dd2- expressingoocytes[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
ONT-093 (30 mg/kg, i.g., twice a day at days 4-6, 11-13, 18-20 and 25-27) enhances the antitumor activity of Paclitaxel (HY-B0015) in MDR breast and colon carcinoma xenograft mice models[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MDR breast and colon carcinoma xenograft mice models[1]
-
Dosage:30 mg/kg, companied Paclitaxel (15 mg/kg)
-
Administration:Orally gavage, twice a day at days 4-6, 11-13, 18-20 and 25-27
-
Result:Reduced tumor weight.
化学情報
-
CAS 番号 216227-54-2
-
性状 Solid
-
分子量 494.67
-
分子式 C32H38N4O
-
Color Light yellow to yellow
-
SMILES
CC(C)NC1=CC=C(C2=C(C3=CC=C(NC(C)C)C=C3)N=C(C4=CC=C(/C=C/COCC)C=C4)N2)C=C1
-
別名
OC 144-093; OC 144093
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
体外:
Methanol : 125 mg/mL (252.69 mM; Need ultrasonic)
DMSO : 100 mg/mL (202.15 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (273 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Newman MJ, et al. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res. 2000 Jun 1;60(11):2964-72. [Content Brief]
[2]. Chi KN, et al. A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. Invest New Drugs. 2005 Aug;23(4):311-5. [Content Brief]
[3]. Sanchez CP, et al. Polymorphisms within PfMDR1 alter the substrate specificity for anti-malarial drugs in Plasmodium falciparum. Mol Microbiol. 2008 Nov;70(4):786-98. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / Methanol | 1 mM | 2.0215 mL | 10.1077 mL | 20.2155 mL | 50.5387 mL |
| 5 mM | 0.4043 mL | 2.0215 mL | 4.0431 mL | 10.1077 mL | |
| 10 mM | 0.2022 mL | 1.0108 mL | 2.0215 mL | 5.0539 mL | |
| 15 mM | 0.1348 mL | 0.6738 mL | 1.3477 mL | 3.3692 mL | |
| 20 mM | 0.1011 mL | 0.5054 mL | 1.0108 mL | 2.5269 mL | |
| 25 mM | 0.0809 mL | 0.4043 mL | 0.8086 mL | 2.0215 mL | |
| 30 mM | 0.0674 mL | 0.3369 mL | 0.6738 mL | 1.6846 mL | |
| 40 mM | 0.0505 mL | 0.2527 mL | 0.5054 mL | 1.2635 mL | |
| 50 mM | 0.0404 mL | 0.2022 mL | 0.4043 mL | 1.0108 mL | |
| 60 mM | 0.0337 mL | 0.1685 mL | 0.3369 mL | 0.8423 mL | |
| 80 mM | 0.0253 mL | 0.1263 mL | 0.2527 mL | 0.6317 mL | |
| 100 mM | 0.0202 mL | 0.1011 mL | 0.2022 mL | 0.5054 mL |